Study of FB1001 for two types of optic nerve damage
Part of Brain & nervous system, Eyes & vision clinical trials.
This trial tests a new drug called FB1001 in people who have sudden vision loss from either a certain type of glaucoma or a different optic nerve condition. Researchers want to see if it can help protect the nerve in your eye and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 40 years or older.
- You must have one of two conditions: a recent acute angle-closure glaucoma attack (with high pressure and vision loss) or a recent non-arteritic anterior ischemic optic neuropathy (NAION).
- For the glaucoma group, your highest eye pressure during the attack was at least 30 mmHg, and your current pressure is under 21 mmHg before taking the drug.
- For the NAION group, your symptoms started within the last 14 days and your vision is at least 20/80 (15 letters on a standard eye chart).
- You cannot have other serious eye diseases that might affect your vision, and you must not have had recent eye surgery or certain treatments.
- You must agree to use effective birth control for 3 months after the last dose if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study evaluates new guidelines for diagnosing optic neuritis, a condition where the nerve that carries vision becomes inflamed. If you have sudden vision loss in one or both eyes and your doctor thinks optic neuritis might be the cause, this trial will help confirm the diagnosis using updated diagnostic criteria.
This study uses MRI scans to look at inflammation in blood vessels around the eye in two conditions: giant cell arteritis (GCA, a type of blood vessel inflammation) and ischemic optic neuropathy (a condition where the optic nerve doesn't get enough blood). The goal is to better understand how inflammation affects the optic nerve and vision, which could help guide future treatments.
This trial tests whether a new drug, ER-100, is safe for people with glaucoma or a sudden optic nerve injury called NAION. It aims to see if the drug can be given without serious side effects.
This trial tests a nose spray medication (cenegermin) for people who recently lost vision due to a specific type of optic nerve damage (NAION). The goal is to see if it can help restore sight when started within two weeks of vision loss.
This trial tests a new medicine called PYC-001, given as an injection into the eye, for people with a specific genetic form of vision loss called autosomal dominant optic atrophy (ADOA). It aims to see if the treatment is safe and could help protect or improve vision.
This trial tests an investigational eye drop called ASP2767 to see if it is safe and can help slow or prevent further vision loss in people with advanced glaucoma-related optic nerve damage.
Hear when a new Optic Neuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.